Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Published:2017-01-17 Issue:6 Volume:123 Page:994-1002
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Garcia‐Manero Guillermo¹,Montalban‐Bravo Guillermo¹,Berdeja Jesus G.²,Abaza Yasmin¹,Jabbour Elias¹,Essell James³,Lyons Roger M.⁴,Ravandi Farhad¹,Maris Michael⁵,Heller Brian⁶,DeZern Amy E.⁷,Babu Sunil⁸,Wright David⁹,Anz Bertrand¹⁰,Boccia Ralph¹¹,Komrokji Rami S.¹²,Kuriakose Philip¹³,Reeves James¹⁴,Sekeres Mikkael A.¹⁵,Kantarjian Hagop M.¹,Ghalie Richard¹⁶,Roboz Gail J.¹⁷

Affiliation:

1. Department of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston Texas

2. Sarah Cannon Research InstituteNashville Tennessee

3. Oncology/Hematology CareCincinnati Ohio

4. Cancer Care Center of South TexasSan Antonio Texas

5. Colorado Blood Cancer InstituteDenver Colorado

6. Southern Cancer CenterDaphne Alabama

7. Sidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimore Maryland

8. Fort Wayne Medical Oncology and HematologyFort Wain Indiana

9. Florida Cancer Specialists‐NorthJacksonville Florida

10. Tennessee OncologyChattanooga Tennessee

11. Center for Cancer and Blood DisordersBethesda Maryland

12. H. Lee Moffitt Cancer CenterTampa Florida

13. Department of Internal MedicineDivision of Hematology Oncology, Henry Ford HospitalDetroit Michigan

14. Florida Cancer Specialists‐SouthCape Coral Florida

15. Leukemia Program, Cleveland ClinicCleveland Ohio

16. MEI PharmaSan Diego California

17. Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.30533

Reference36 articles.

1. International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

2. Revised International Prognostic Scoring System for Myelodysplastic Syndromes

3. Decitabine improves patient outcomes in myelodysplastic syndromes

4. A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines

5. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond the horizon: emerging therapeutic approaches in myelodysplastic neoplasms;Experimental Hematology;2024-02

2. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes;Cancer Treatment Reviews;2024-02

3. Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial;Cancer Medicine;2023-06-23

4. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study;Journal of Clinical Oncology;2023-05-20

5. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies;Signal Transduction and Targeted Therapy;2023-02-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3